A股異動丨埃夫特升超12%創近2個月新高,擬19億元投建機器人超級工廠
埃夫特-U(688165.SH)盤初一度升12.48%報8.47元,創6月初以來新高。消息面上,埃夫特昨晚披露,擬以不超過19億元資金,在安徽省蕪湖市通過購買土地,建設機器人超級工廠暨全球總部項目,以實現埃夫特工業機器人業務產能的增加。該項目分兩期建設實施,規劃將面向高端應用場景、特種應用場景和補全產品譜系三個方向進行新產品開發。預計一期建設完成後年產5萬台高性能工業機器人,二期完成後年產10萬台。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.